Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, PARP inhibition in cancer therapy, and Cancer Immunotherapy and Biomarkers.
Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial)
390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial
[<sup>68</sup>Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).
Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.